These changes were reversible with Drp1 inhibition, making it a promising therapeutic candidate in MDS patients harboring RUNX1 mutation/RUNX1/RUNX1T1 fusion gene [120]. This evidence concerns the gene DNM1L and myelodysplastic syndrome.